Skip to main content
. 2017 Jun 22;8(43):74006–74018. doi: 10.18632/oncotarget.18598

Figure 6. Schematic representation that summarizes the proposed mechanism of action of CBP501 as described in the text.

Figure 6

CBP501 interacts with CaM, blocking its observed (or potential) interactions with KRas, GPCRs or IL-6R, thereby affecting a variety of pathways related to cell migration, invasion and EMT. GFRs, growth factor receptors; GPCRs, G protein-coupled receptors; IL-6R, interleukin-6 receptor.